Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Women with polycystic ovary syndrome (now called polyendocrine metabolic ovarian syndrome, or PMOS) may face a higher risk of Alzheimer's disease and dementia, according to a new review. The link appears to be largely driven by metabolic conditions like obesity and insulin resistance rather than PMOS itself. Researchers say more studies are needed before any PMOS-specific neuroprotective treatments can be recommended.
Women with polycystic ovary syndrome — recently rebranded as polyendocrine metabolic ovarian syndrome (PMOS) — may be at elevated risk for Alzheimer's disease and related dementias, according to a review published in the Journal of the Endocrine Society. Researchers analyzed studies on PCOS/PMOS and cognitive outcomes, finding that affected individuals performed worse on executive function, attention, and memory tests compared to healthy controls.
But here's the nuance: the elevated risk appears to be largely mediated by metabolic conditions like obesity, insulin resistance, dyslipidemia, and chronic inflammation — not PMOS independently. Some studies found higher levels of amyloid precursor protein and apolipoprotein E in people with PCOS/PMOS, biomarkers typically associated with Alzheimer's and type 2 diabetes, particularly in those with obesity.
Key Takeaways:
Why it matters: PMOS and Alzheimer's disease both disproportionately affect women, making this potential overlap clinically significant. Understanding whether and how PMOS raises dementia risk could open new avenues for early intervention — but for now, managing metabolic health remains the most actionable step.
